GLP-1 Receptor Agonists in Perimenopause: VAT Aromatase Reduction, Cytokine-Mediated Hot Flash Pathways, and Estrogen Metabolism

[Image: VAT versus SAT aromatase activity in perimenopause showing CYP19A1 expression differences]

Aromatase (CYP19A1) catalyzes the conversion of androstenedione and testosterone to estrone and estradiol, respectively. In premenopausal women, ovarian CYP19A1 produces predominantly estradiol, with peripheral adipose CYP19A1 contributing a secondary, lower-affinity estrone-dominant pool. As perimenopausal ovarian function declines, peripheral adipose aromatization becomes the primary estrogen source — a transition that occurs proportionally to VAT mass, as VAT expresses CYP19A1 at higher levels per gram than SAT.

GLP-1RAs drive preferential VAT reduction through mechanisms that include direct GLP-1R signaling in visceral adipocytes (promoting lipolysis via cAMP/PKA and HSL activation), normalization of insulin — which is a potent anti-lipolytic in visceral fat — and reduction of adipokine-driven lipogenesis. The 1.6:1 VAT:SAT reduction ratio observed in DXA-measured studies means that a 10% total body weight reduction produces approximately 16% of that reduction from VAT. In practical terms, this substantially attenuates peripheral CYP19A1 activity.

The clinical consequence is a downward shift in estrone production and a shift in the estrone:estradiol ratio. Because estradiol binds estrogen receptors (ERα and ERβ) with approximately 10-fold higher affinity than estrone, a reduction in the estrone-dominant peripheral pool may have less impact on ERα-mediated beneficial effects (cardiovascular, bone) than the absolute estrogen decline suggests. However, the loss of peripheral estrone buffer in women approaching menopause — particularly those who are not using HRT — can precipitate or unmask vasomotor symptoms, a clinical consideration requiring proactive management.

[Image: Hypothalamic thermoregulatory set point showing estrogen and cytokine influences on hot flash threshold]

Vasomotor symptoms (VMS) in perimenopause — hot flashes and night sweats — involve thermoregulatory dysregulation mediated by estrogen withdrawal acting on the hypothalamic thermoregulatory set point, with amplification through inflammatory cytokine networks. IL-6 and TNF-α, both elevated in metabolic dysfunction and VAT accumulation, lower the thermoregulatory threshold, increasing VMS frequency and severity. C-reactive protein, downstream of IL-6, correlates positively with VMS severity in multiple epidemiological cohorts.

GLP-1RAs produce sustained reductions in circulating IL-6 (mean ~15-20% reduction in 24-week trials), TNF-α, and CRP through a combination of VAT reduction (adipose tissue is the dominant IL-6 source), direct GLP-1R signaling on macrophages and hepatocytes (reducing NF-κB-driven cytokine synthesis), and normalization of the glucose-insulin axis (hyperglycemia independently drives IL-6 and CRP production). This anti-inflammatory mechanism is physiologically distinct from and additive to the estrogenic pathway for VMS management.

Estrogen decline in perimenopause also reduces endogenous GLP-1 sensitivity at the receptor level, partly through downregulation of GLP-1R expression in hypothalamic thermoregulatory centers. Pharmacological GLP-1R agonism bypasses this reduced sensitivity, providing effective receptor engagement despite the low-estrogen environment. This may explain the clinical observation that perimenopausal women sometimes achieve greater metabolic response per kilogram of GLP-1RA-induced weight loss than premenopausal controls with similar baseline characteristics.

[Image: HPA axis sleep-cortisol diagram showing cortisol effects on VAT accumulation and GLP-1 interruption point]

Perimenopause disrupts sleep architecture through multiple mechanisms: VMS-induced arousal, estrogen-mediated REM regulation, and progesterone withdrawal (progesterone metabolite allopregnanolone has potent GABA-A modulatory properties that promote deep sleep). Sleep fragmentation and reduced slow-wave sleep duration in perimenopause increase 24-hour cortisol area under the curve, particularly evening and early morning cortisol excursions. Cortisol excess specifically promotes VAT accumulation via glucocorticoid receptor-mediated upregulation of LPL (lipoprotein lipase) in visceral adipocytes.

GLP-1RAs improve sleep architecture through mechanisms including: reduction of VMS that cause arousal; lower visceral fat mass and associated IL-6 production (IL-6 disrupts delta wave sleep); and normalization of insulin, which is associated with nighttime glucose volatility that triggers arousals. Studies in metabolically dysregulated populations demonstrate 8-15% increases in slow-wave sleep and reduced AHI (apnea-hypopnea index) with GLP-1RA treatment. Improved slow-wave sleep normalizes HPA axis suppression through appropriate overnight GH/IGF-1 pulsatility, reducing early morning cortisol overshoot.

The downstream metabolic consequence is a reduction in cortisol-driven VAT accumulation, creating a virtuous cycle: GLP-1RA reduces VAT → less IL-6 → better sleep → better cortisol rhythm → less VAT deposition → further IL-6 reduction. Conversely, the perimenopausal pattern without intervention represents a negative feedback loop: poor sleep → elevated evening cortisol → preferential VAT deposition → more IL-6 → worse sleep architecture.

[Image: L-cell GLP-1 secretion pathway showing estrogen receptor modulation and pharmacological bypass]

Endogenous GLP-1 is secreted from intestinal L-cells in response to nutrient ingestion and serves as a key regulator of postprandial insulin secretion, appetite, and gastric emptying. Estrogen receptors (primarily ERα) are expressed on L-cells and at the level of the GLP-1R on target tissues including the pancreas, brain, and adipose tissue. Estrogen has been shown to enhance L-cell GLP-1 secretion and to sensitize GLP-1R signaling in pancreatic beta cells.

In perimenopause, irregular estrogen oscillations — often with supraphysiological spikes early in perimenopause followed by precipitous drops — create unstable GLP-1 sensitivity. The mean trend is toward reduced effective GLP-1 signaling as estrogen levels decline toward the late perimenopausal nadir. This is one physiological mechanism contributing to the metabolic decompensation of perimenopause: the same food intake and physical activity that maintained metabolic homeostasis in premenopause becomes insufficient because endogenous GLP-1 signaling is attenuated.

Pharmacological GLP-1RAs bypass this sensitivity decline by providing supraphysiological GLP-1R engagement that is estrogen-independent. The receptor occupancy achieved by semaglutide or tirzepatide is sufficient to drive full downstream signaling regardless of estrogen-mediated modulation of receptor sensitivity. This is a mechanistically distinct benefit from the weight loss or VAT reduction effects — it restores the functional capacity of a system that perimenopause has degraded, independent of body composition changes.